Lilly/Entos Deal Reinforces the Significance of Delivery Mechanisms for Nucleic Acid-Based Therapies
As part of a research partnership aimed at improving the delivery of nucleic acid-based therapies targeting nervous system diseases, American pharmaceutical company Eli Lilly and